Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide

Hui Shi[1,2], Alex A. Gandhi[1], Stephanie A. Smith[3], Diane Chiang[1], Srilakshmi Yalavarthi[1], Ramadan A. Ali[1], Chao Liu[1], Gautam Sule[1], Pei-Suen Tsou[1], Yu Zuo[1], Yogendra Kanthi[3,4], James H. Morrissey[3], and Jason S. Knight[1]

Affiliations

[1] Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

[2] Division of Rheumatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

[3] Department of Biological Chemistry, University of Michigan, Ann Arbor, Michigan, USA, 20892

[4] Division of Intramural Research National Heart, Lung and Blood Institute Bethesda, Maryland, USA

[5] Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Correspondence

Jason S. Knight, MD, PhD

jsknight@umich.edu

ABSTRACT

Neutrophil-mediated activation and injury of the endothelium play a role in the pathogenesis of diverse disease states ranging from autoimmunity to cancer to COVID-19. Neutralization of cationic proteins (such as neutrophil extracellular trap/NET-derived histones) with polyanionic compounds has been suggested as a potential strategy for protecting the endothelium from such insults. Here, we report that the FDA-approved polyanionic agent defibrotide (a pleotropic mixture of oligonucleotides) directly engages histones and thereby blocks their pathological effects on endothelium. *In vitro*, defibrotide counteracted endothelial cell activation and cell death, whether triggered by purified NETs, COVID-19 serum containing high levels of NETs, or recombinant histone H4. *In vivo*, defibrotide stabilized the endothelium and protected against histone-accelerated inferior vena cava thrombosis in mice. Mechanistically, defibrotide demonstrated direct and tight binding to histone H4 as detected by both electrophoretic mobility shift assay and surface plasmon resonance. Taken together, these data provide insights into the potential role of polyanionic compounds in protecting the endothelium from thromboinflammation with potential implications for myriad NET- and histone-accelerated disease states.

INTRODUCTION

Neutrophils are the most abundant innate effector cells of the human immune system, exerting antimicrobial effects through phagocytosis and degranulation[1]. The release of neutrophil extracellular traps (**NETs**)—web-like structures composed of microbicidal cytosolic and granule proteins enmeshed in decondensed chromatin—is a recently described strategy by which neutrophils kill microbes in tissues[2]. However, when formed intravascularly, NETs are potentially noxious, trapping red blood cells, activating platelets, and damaging the endothelium—thereby promoting coagulation, vascular occlusion, and thrombosis[3-6]. Endothelial activation and injury driven by NETs has been revealed as a key pathogenic step in a variety of disease states including deep vein thrombosis[7], transfusion-related acute lung injury[8], atherosclerosis[9], and lupus[10]. Very recently, high levels of NETs were detected in the blood of coronavirus disease 2019 (COVID-19) patients[11], where they likely activate contribute to the endothelial damage regularly noted on the histopathology of COVID-19 organs[12-15] .

NETs present a variety of highly cationic proteins, including histones, HMGB1, calprotectin, cathepsin G, and LL-37, among others. While these proteins contribute to the capture and inactivation of invading microorganisms, they may also be cytotoxic to host tissues[16]. To this end, NET-derived histones account for ~70% of NET-associated proteins[16] and have been associated with endothelial damage and multiple organ dysfunction in acute states such as sepsis[17], acute pancreatitis[18], acute respiratory distress syndrome[19], and severe trauma[20]. High levels of circulating histones (up to 250 µg/ml after trauma)[20] activate and damage endothelial cells via pore formation[21,22], engagement of innate sensors such as Toll-like receptors[23-25] and the NLRP3 inflammasome[26,27], and forced release of von Willebrand factor (vWF)[28]. On balance, the result is a hypercoagulable state and an increased risk of vascular events including thrombosis. Targeting histones by neutralizing their cationic nature

with polyanions has been suggested as an approach to combatting various NET- and histone-associated diseases[29,30].

Defibrotide is a pleotropic mixture of oligonucleotides (90% single-stranded phosphodiester oligonucleotides and 10% double-stranded) that is derived from porcine intestinal mucosal DNA and which has antithrombotic, fibrinolytic, and anti-inflammatory activities[31,32]. Defibrotide was initially approved for the treatment of thrombophlebitis and as prophylaxis for deep vein thrombosis in Italy[33,34] (although these approvals are no longer active). Subsequently, it was granted an orphan drug designation by European and American regulatory agencies for the treatment of serious hepatic veno-occlusive disease (VOD) after hematopoietic cell transplantation (Europe) or VOD with renal and/or pulmonary dysfunction post-transplant (United States)[34]. Although defibrotide's mechanisms of action remain incompletely understood, there is evidence that it protects endothelium, modulates platelet activation, potentiates fibrinolysis, decreases thrombin generation and activity, and reduces circulating levels of plasminogen activator inhibitor type 1[35-39]. Defibrotide has also been demonstrated to associate with cationic proteins, for example collagen I[40].

Here, we hypothesized that the polyanionic properties of defibrotide might mitigate damage to the endothelium by NETs and especially NET-derived cationic proteins. In pursuit of this possibility, we characterized defibrotide's endothelium-protective properties both *in vitro* and in a mouse model of venous thrombosis.

RESULTS

Defibrotide inhibits the activation of cultured endothelial cells by NETs. Human umbilical vein endothelial cells (HUVECs) were cultured with human neutrophil-derived NETs in the presence or absence of defibrotide. To gauge the adhesive potential of the cultured HUVECs, gene transcripts associated with the expression of E-selectin, ICAM-1 and VCAM-1 were quantified. In all cases, expression was markedly increased by NETs (**Figure 1A-C**), with expression subsequently mitigated by defibrotide (**Figure 1A-C**). We reasoned that if these gene expression differences were functionally meaningful, then adhesion of neutrophils to the HUVEC monolayer should track in similar fashion (increased by NETs and decreased by defibrotide). As predicted, calcein-AM-labeled human neutrophils adhered more strongly to NET-activated HUVECs, an effect that was reduced in the presence of defibrotide (**Figure 1D**). Beyond surface adhesion molecules, previous work has also suggested that NETs upregulate expression of tissue factor (TF) by endothelial cells, thereby contributing to the prothrombotic state[41]. Here we found that TF was upregulated by NETs whether measured by gene expression (**Figure 1E**) or enzymatic activity (**Figure 1F**); in both contexts, NET-mediated increases were significantly reduced by defibrotide (**Figure 1E-F**). Taken together, these data support the basic premise of the study, namely that defibrotide can neutralize the activation of endothelial cells by NETs.

Defibrotide reduces HUVEC activation by COVID-19 serum. The work of our group and many others has demonstrated high levels of NETs in the circulation of patients with COVID-19, where NETs appear to track closely with disease severity[42]. We therefore reasoned that defibrotide might be able to reduce activation of endothelial cells by COVID-19 serum. To address this, we developed an in-cell ELISA platform compatible with our Biosafety Level-3 facility (**Figure 2A**). We first confirmed that purified NETs would increase surface expression of E-selectin, ICAM-1, and VCAM-1 in this assay, and that these increases could be mitigated by

defibrotide (**Figure 2B-D**). Consistent with our hypothesis, we found a similar upregulation of surface E-selectin (**Figure 2E**), ICAM-1 (**Figure 2F**) and VCAM-1 (**Figure 2G**) when HUVECs were cultured with pooled COVID-19 serum, with that upregulation partially counteracted by defibrotide. In summary, these data support the idea that defibrotide can reduce activation of endothelial cells by NETs, and hint at potential clinical utility in diseases such as COVID-19.

Transcriptome profiling confirms a NET-induced proinflammatory signature in endothelial cells, which can be mitigated by defibrotide. The above data demonstrate activation of endothelial cells by NETs in the context of selected genes associated with cell-cell interactions and coagulation. To more broadly understand the pathways associated with endothelial cell activation, we performed RNA sequencing of HUVECs exposed to vehicle, NETs, or NETs + defibrotide. We identified 440 differentially expressed genes (300 upregulated) in HUVECs upon NET stimulation as compared with vehicle. Conversely, there were 229 differentially expressed genes (192 downregulated) when the NETs + defibrotide group was compared to NETs alone. The top regulated genes are displayed in **Figure 3A**. Functional gene network analysis of upregulated genes in NET-stimulated HUVECs revealed an inflammatory signature highlighted by meta groups such as the TNF signaling pathway, NF-κB signaling pathway, and MAPK signaling pathway (**Figure 3B**). Notably, the same pathways that were upregulated by NETs were likely to be downregulated by defibrotide (**Figure 3C**). Genes downregulated by NETs were also assessed by functional gene network analysis. Important pathways related to cell growth and anti-inflammation were downregulated by NETs, including the Hippo signaling pathway, cAMP signaling pathway, and TGF-β signaling pathway (**Figure 3D**). These same pathways were then upregulated when defibrotide was added to NETs (**Figure 3E**). Taken together, these data confirm the ability of NETs to activate endothelial cells, and demonstrate the ability of defibrotide to reverse those effects.

Blocking histone H4 counteracts HUVEC activation by NETs. As discussed above, part of the original hypothesis was that the polyanionic nature of defibrotide might make it especially effective at neutralizing NET-derived cationic proteins such as histones[2], which are important mediators of inflammation, tissue injury, and organ dysfunction in the extracellular space[43,44]. To begin to address this, we asked whether a histone-neutralizing antibody might be effective in our system. Indeed, an anti-histone H4 antibody counteracted the upregulation of HUVEC E-selectin (**Figure 4A**), ICAM-1 (**Figure 4B**), VCAM-1 (**Figure 4C**), and TF (**Figure 4D**) by NETs.

Defibrotide abolishes HUVEC activation by extracellular histone H4. We next asked whether defibrotide might directly antagonize the effects of histone H4. As expected, purified histone H4 increased expression of E-selectin (**Figure 5A**), ICAM-1 (**Figure 5B**), and VCAM-1 (**Figure 5C**) by HUVECs, while defibrotide almost completely abolished these effects. Mechanistically, both TLR2 and TLR4 were involved in histone H4-mediated endothelial cell activation (**Supplementary Figure 2**) as has been previously reported[45]. Inflammatory cytokines (IL-8 and MCP-1) in HUVEC supernatants also increased upon exposure to histone H4 and were subsequently suppressed by defibrotide (**Supplementary Figure 1**). Similar patterns were also observed for TF gene expression (**Figure 5D**) and enzymatic activity (**Figure 5E**). Given these findings, along with the RNA sequencing data, we investigated whether defibrotide might be working to counterbalance intracellular signaling pathways associated with TLRs or TNF signaling. However, in our hands, defibrotide's protective properties did not extend to HUVEC activation by either LPS or TNF-α (**Supplementary Figure 3**). We next tested whether defibrotide might work through direct engagement with histone H4 in the extracellular space. Indeed, using an electrophoretic mobility shift assay (EMSA)[46], we found evidence of a direct interaction between histone H4 and defibrotide in that histone H4 could retard the migration of defibrotide (a mixture of oligonucleotides) through an agarose gel (**Figure 5F**). In contrast, histone H4 had no impact on the migration of bovine serum

albumin. A strong interaction between histone H4 and defibrotide was also confirmed by surface plasmon resonance. Assuming an average molecular weight of defibrotide as 16.5 kilodaltons, the equilibrium dissociation constant (K_D) between defibrotide and histone H4 was calculated as 53.5 nM (**Figure 5G**).

Defibrotide strongly protects endothelial cells against histone H4-induced cell death. The above assays were focused on relatively short cell culture times, typically 6 hours. However, we questioned whether the impact of defibrotide on histone H4-mediated HUVEC activation would persist over longer periods of time. As reported previously, histones go beyond endothelial cell activation and become cytotoxic upon prolonged exposure in culture[22,47]. Indeed, we found remarkable protection of cell viability by defibrotide over a 24-hour period (**Figure 6A**). To further confirm these findings, we varied the experiment by introducing kinetic monitoring of surface phosphatidylserine exposure as measured by Annexin V binding. We found a dose-dependent relationship between histone H4 and Annexin V binding (**Supplementary Figure 4**), and found strong and stepwise protection when HUVECs were also cultured with defibrotide concentrations ranging from 10-40 µg/ml (**Figure 6B**). We also found increased levels of both IL-1β and IL-18 in culture supernatants, both of which were reduced by defibrotide (**Figure 6C-D**), supporting the idea that histone H4-mediated cell death may be on the spectrum of pyroptosis. To further substantiate these data, we also assessed translocation and subsequent release of the alarmin HMGB1, which is known to track with inflammatory forms of cell death including pyroptosis[48]. By microscopy, we observed the translocation of HMGB1 from nucleus to cytoplasm upon exposure of HUVECs to histone H4, with reversal of this effect by defibrotide (**Figure 6E**). Measurement of HMGB1 in culture supernatants mirrored these findings, with histone H4 triggering HMGB1 release and defibrotide neutralizing that effect (**Figure 6F**). Taken together, these data demonstrate that longer-term exposure of HUVECs to histone H4 triggers cell death (which may be of

a proinflammatory nature) and that defibrotide's anti-histone effects are sustained in culture for up to 24 hours.

Defibrotide counters histone-accelerated venous thrombosis in mice. To determine the potential *in vivo* relevance of these findings, we employed a model of venous thrombosis in which a constricting ligature is fixed around the inferior vena cava (IVC) and then the presence and potential characteristics of thrombosis are assessed 24 hours later (**Figure 7A**)[6,49]. First, we asked whether thrombus accretion was impacted by injection of calf thymus histones, and indeed found this to be the case (**Figure 7B-C**). As part of these experiments, we also administered defibrotide intravenously shortly after injection of the histones. With this approach, both thrombus accretion (**Figure 7B-C**) and thrombus length (**Supplementary Figure 5**) were reduced essentially to the levels seen in control mice. In support of endothelial cell activation contributing to the histone-accentuated thrombosis phenotype, both soluble E-selectin and soluble P-selectin tracked closely with thrombus accretion (**Figure 7D-E**), as did infiltration of leukocytes, whether scored as Ly6G+ (neutrophils) or CD45+ (most leukocytes) (**Figure 7F-H**). In support of this concept, there was a strong correlation between either soluble E-selectin or soluble P-selectin and thrombus size (**Supplementary Figure 6**). Taken together, these data confirm the proinflammatory and prothrombotic impact of histones *in vivo* and demonstrate that defibrotide has the potential to neutralize these properties.

DISCUSSION

As evidence continues to implicate NETs and NET-derived histones in the pathophysiology of disease states ranging from infection (including COVID-19) to autoimmunity to cancer[50], the search for NET-targeting therapeutics takes on additional importance. Here, we explored the extent to which an FDA-approved drug defibrotide might protect endothelial cells from NETs and extracellular histones. We found defibrotide to counteract endothelial cell activation and hypercoagulability triggered by NETs, COVID-19 serum with high NETs, and histone H4. Mechanistically, our evidence points to a direct interaction between defibrotide and cationic proteins such as histone H4 as an important aspect of these protective effects.

Polyanionic substances naturally exist in the extracellular environment where they play a variety of biological roles[51]. Unfractionated heparin and suramin are examples of how polyanionic drugs may be leveraged clinically with the potential to bind cationic microbe-derived proteins as well as cationic tumor cytokines/receptors for treatment of infectious diseases and cancer, respectively[52-56]. In previous work, defibrotide's polyanionic properties have been shown to include binding with high affinity to specific heparin-binding proteins including basic fibroblast growth factor (bFGF)[40]. Interestingly, defibrotide (oligonucleotides) and heparins (proteoglycans) share similarities in charge distributions and binding patterns[57].

Histones bind DNA tightly mainly due to charge-charge interactions, with a possible role for specific DNA sequence motifs[58]. Our results found a strong interaction between histone H4 and defibrotide, which was very resistant to dissociation. Considering defibrotide is a natural product (i.e., not produced by a DNA synthesizer), the possibility of any specific sequence dominating its effect is low. We therefore speculate that the main binding force between histone H4 and defibrotide also comes from charge-charge interactions. An interesting unknown is the extent to

which the degradation of defibrotide *in vivo* may be delayed upon binding histone H4. Typically, phosphodiester oligonucleotides would be rapidly degraded in plasma; however, we found a protective role in an animal model over 24 hours without the need for redosing. A deeper understanding of these *in vivo* properties should be a priority for future research.

As a major component of NETs, histones are responsible for microvascular dysfunction during sepsis where they trigger neutrophil migration, endothelial injury, hemorrhage, and thrombosis[17]. Compared with other histones, histone H4 has the strongest impact on platelets, enhancing thrombin generation and accelerating thrombosis[59]. Histone H4 has also been reported as the major histone mediator of membrane lysis of smooth muscle cells and arterial tissue damage and inflammation in atherosclerosis[60]. Our study has now also revealed that neutralizing histone H4 significantly mitigates NET-mediated activation of HUVECs. Whether defibrotide preferentially neutralizes histone H4 as compared with other histones is an area deserving of further research.

Multiple organ dysfunction syndrome (MODS) is widely considered to be the leading cause of morbidity and mortality for patients admitted to an intensive care unit, where it encompasses heterogeneous disease states such as sepsis, shock, trauma, severe burn, and pancreatitis[61-64]. Systemic inflammation and vascular coagulopathy account for the main pathological processes of MODS[65], and of course also characterize aspects of COVID-19[66-69] and the closely related catastrophic antiphospholipid syndrome[70]. In MODS, endothelial cell activation is considered a precursor to tissue damage and end-organ dysfunction with upregulation of adhesion molecules triggered by cytokines, microbial proteins, and various cationic proteins from necrotic cells[71]. One recent study evaluated circulating histones in a cohort of 420 ICU patients with sepsis, severe trauma, or severe pancreatitis and identified circulating histones as major mediators of MODS in these patients[72]. One may

consider whether administration of defibrotide in an early phase of MODS might neutralize cationic proteins such as histones to stabilize the endothelium and break the vicious thromboinflammatory cycle. We are hopeful that further preclinical (and soon clinical) work may have the opportunity to explore the potential of defibrotide as a NET- and histone-neutralizing drug.

METHODS

Serum samples from patients with COVID-19. This study complied with all relevant ethical regulations and was approved by the University of Michigan Institutional Review Board (HUM00179409). Pooled serum samples from 5 patients hospitalized with COVID-19 (all requiring mechanical ventilation) and 5 healthy controls were used in this study.

Cell culture and reagents. Human umbilical vein endothelial cells (HUVECs) purchased from ATCC were cultured in EBM supplemented with EGM-2MV singleQuots (Lonza) without hydrocortisone in 0.2% gelatin-coated tissue culture plates. All experiments were performed using HUVECs of passage 6 or lower. Recombinant histone H4 was purchased from Cayman (10264) for *in vitro* experiments. Histone from calf thymus was purchased from Sigma (10223565001). Anti-histone H4 was from Cell Signaling Technology (2592). TLR2 inhibitor C29 was from Medchemexpress (HY-100461) and TLR4 inhibitor TAK 242 was from Sigma (614316).

NET isolation. Neutrophil extracellular traps (NETs) were generated as described previously[73].

Quantitative polymerase chain reaction (qPCR). Total RNA was isolated using Direct-zol RNA MiniPrep kit (Zymo Research) according to manufacturer's instructions. 200 ng of RNA from each sample was reverse-transcribed using random hexamer primed single-strand cDNA (10 min at 25 °C, 15 min at 42 °C, 5 min at 99 °C) by MMLV Reverse Transcriptase (Life technologies). cDNA was amplified using Fast SYBR Green Mastermix (Life Technologies) on a ViiA7- Realtime qPCR System (Life Technologies). Expression level of mRNAs were normalized to β-actin. All gene primers were purchased from Qiagen.

Neutrophil adhesion assay. Monolayer HUVECs were cultured with or without NETs for 4 hours. Isolated fresh neutrophils were labeled with calcein-AM (C1430, Thermo) for 30 minutes at 37°C, and then 6×10^5 neutrophils per well were added to the washed (RPMI + 3% BSA) monolayer for 20 minutes. After washing with pre-warmed HBSS, adherent neutrophil fluorescence was measured with a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek) at 485 and 535 nm (excitation and emission wavelengths, respectively).

TF activity. Cell lysates were prepared with 150 µl 15 mM octyl-ß-D-glycopyranoside (Sigma) for 15 min at 37°C. TF activity was measured using TF Human Chromogenic Activity Assay Kit (ab108906, Abcam) according to the manufacturer's instructions.

In-cell ELISA. In the Biosafety Level-3 facility, confluent monolayers of HUVECs in 96-well microplates were incubated with 2.5% serum or NETs for 6 hours. Some cultures were additionally supplemented with defibrotide. Cells were fixed by adding an equal volume of 8% paraformaldehyde for 30 minutes. Blocking was with 2x blocking solution (ab111541, Abcam) at room temperature for 2 hours. After washing with PBS, cells were incubated with 5 µg/ml primary mouse anti-human antibodies against E-selectin (BBA26, R&D), VCAM-1 (BBA5, R&D), or ICAM-1 (ab2213, Abcam) at 4°C overnight. Next, 100 µl of diluted horseradish peroxidase conjugated rabbit anti-mouse IgG (1:2000, Jackson ImmunoResearch) in 1x blocking solution was added and incubated at room temperature for 1 hour. After washing thoroughly with PBS, 100 µl of TMB substrate was added, and blue color development was measured at OD 650 nm with a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek). The signals were corrected by subtracting the mean signal of wells incubated in the absence of the primary antibody.

RNA-sequencing. Total RNA from cells was isolated using RNeasy Plus Mini Kit (74134, Qiagen) according to manufacturer's instructions. Sequencing was

performed by the UM Advanced Genomics Core, with libraries constructed and subsequently subjected to 150 paired-end cycles on the NovaSeq-6000 platform (Illumina). FastQC (v0.11.8) was used to ensure the quality of data, and sequence alignment were trimmed adapters using Cutadapt (v2.3). Reads were mapped to the reference genome GRCh38 (ENSEMBL) using STAR (v2.6.1b) and assigned count estimates to genes with RSEM (v1.3.1). Alignment options followed ENCODE standards for RNA-seq. FastQC was used in an additional post-alignment step to ensure that only high-quality data were used for expression quantitation and differential expression. Differential expression data were pre-filtered to remove genes with 0 counts in all samples. Differential gene expression analysis was performed using DESeq2, using a negative binomial generalized linear model (thresholds: linear fold change >1.5 or <-1.5, Benjamini-Hochberg FDR (Padj) <0.05). Plots were generated using variations of DESeq2 plotting functions and other packages with R version 3.3.3. Functional analysis, including candidate pathways activated or inhibited in comparison(s) and GO-term enrichments, was performed using iPathway Guide (Advaita).

Quantification of cytokines. Cytokines were quantified in supernatants using human IL-1β DuoSet ELISA kit (DY201, R&D systems), human IL-18 ELISA Kit (7620, MBL International), human IL-8 DuoSet ELISA kit (DY208, R&D systems), and human MCP-1 DuoSet ELISA kit (DY279, R&D systems), according to the manufacturers' instructions.

Electrophoretic mobility shift assay (EMSA). 10 μg of defibrotide was incubated with various concentrations (40 μM, 80 μM, 120 μM) of histone H4 in serum-free RPMI for 1 hour at 37°C to form complexes. 120 μM bovine serum albumin was used as a negative protein control. Complexes were then run on a 0.5% agarose gel stained with SYBR safe (Invitrogen) for 30 minutes. The gel was imaged on a Typhoon FLA 7000 biomolecular imager (GE Healthcare).

Surface Plasmon Resonance (SPR) assay. SPR studies were performed using the Biacore T200 with His-tagged histone H4 coupled to a NiNTA chip. Defibrotide in a series of concentrations from 0.39 µg/ml to 12.5 µg/ml was injected over the sensor chip at room temperature, using a running biffer of 50 mM Hepes Naoh pH 7.4, 100 mM NaCl, and 0.002% surfactant P-20. Resonance was corrected for background using a reference cell without histone H4, and curves were blank subtracted using data acquired with running buffer only. Data were analyzed using BIA Evaluation software (GE Healthcare Bio-Sciences, Pittsburgh, PA) to determine binding affinity at steady state. Data shown are representative of 3 independent experiments.

Crystal violet viability staining. Cell viability was tested by crystal violet staining as reported previously[74].

Annexin V staining. Cells were seeded into a 96-well plate and allowed to adhere overnight. Annexin V reagent (Incucyte Annexin V Green Reagent for Apoptosis; Essen Bioscience, final dilution of 1:200) was added together with histone H4 with or without defibrotide on the following day. Annexin V staining was monitored with the IncuCyte® S3 microscopy system every 1 hour for 30 hours. Excitation and emission wavelengths were 490 nm and 515 nm, respectively. Images were collected by a Nikon 20x objective. IncuCyte® S3 integrated software (Essen Bioscience) was used to minimize background fluorescence and quantify fluorescent objects.

Detection of HMGB1. For immunofluorescence microscopy, 1×10^5/well HUVECs were seeded onto coverslips coated with 0.2% gelatin the day before experiments. The HUVECs were treated with 100 µg/ml histone H4 in the presence or absence of defibrotide for 24 hours. Cells were fixed with 1% paraformaldehyde for 10 minutes, permeabilized with 0.5% TritonX-100 for 10 minutes, and blocked with 5% FBS for 30 minutes. Then the cells were intracellularly stained with 5 µg/ml anti-HMGB1 Alexa Fluor® 594 (clone 3E8, Biolegend) in blocking buffer overnight at 4°C. Images were

collected with a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek). HMGB1 was quantified in supernatants using the HMGB1 ELISA Kit (NBP2-62766, Novus) according to the manufacturer's instructions.

Mouse models of venous thrombosis. All experiments were approved by the University of Michigan IACUC. Male C57BL/6 mice were purchased from The Jackson Laboratory (000664), and used at approximately 10 weeks of age. To model large-vein thrombosis was modeled as we have described previously[6]. Mice were injected with either histone (10 mg/kg) or saline 1 hour prior to surgery via tail vein. Defibrotide (150 mg/kg) or an equal volume of saline were administered intravenously via retro-orbital injection. The first dosage of defibrotide was given 24 hours prior to surgery, and the second dose was delivered just after closure of the abdomen. Thrombus was determined 24 hours later.

Quantification of mouse soluble E-selectin and P-selectin. Soluble E-selectin and P-selectin were quantified in mice sera using the mouse E-selectin Duoset ELISA (DY575, R&D system) and mouse P-selectin Duoset ELISA (DY737, R&D system) according to the manufacturer's instructions.

Statistical analysis. Data analysis was performed with GraphPad Prism software version 8. For continuous variables, group means were compared by either t-test (two groups) or one-way ANOVA (more than two groups); correction for multiple comparisons was by Dunnett's, Sidak's, or Tukey's method. For two independent variables, group means were compared by two-way ANOVA (more than two groups); correction for multiple comparisons was by Dunnett's method. Correlations were tested by Pearson's correlation coefficient. Statistical significance was defined as $p < 0.05$.

REFERENCES

1. Nathan C. Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol*. 2006;6(3):173-182.
2. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. *Science*. 2004;303(5663):1532-1535.
3. Sreeramkumar V, Adrover JM, Ballesteros I, et al. Neutrophils scan for activated platelets to initiate inflammation. *Science*. 2014;346(6214):1234-1238.
4. Semeraro F, Ammollo CT, Esmon NL, Esmon CT. Histones induce phosphatidylserine exposure and a procoagulant phenotype in human red blood cells. *J Thromb Haemost*. 2014;12(10):1697-1702.
5. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. *Proc Natl Acad Sci U S A*. 2010;107(36):15880-15885.
6. Meng H, Yalavarthi S, Kanthi Y, et al. In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. *Arthritis Rheumatol*. 2017;69(3):655-667.
7. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. *J Thromb Haemost*. 2012;10(1):136-144.
8. Savchenko AS, Borissoff JI, Martinod K, et al. VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice. *Blood*. 2014;123(1):141-148.
9. Knight JS, Luo W, O'Dell AA, et al. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. *Circ Res*. 2014;114(6):947-956.
10. Carmona-Rivera C, Zhao W, Yalavarthi S, Kaplan MJ. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. *Ann Rheum Dis*. 2015;74(7):1417-1424.
11. Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. *JCI Insight*. 2020;5(11).
12. Leppkes M, Knopf J, Naschberger E, et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. *EBioMedicine*. 2020;58:102925.
13. Middleton EA, He X-Y, Denorme F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. *Blood*. 2020;136(10):1169-1179.
14. Veras FP, Pontelli MC, Silva CM, et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. *J Exp Med*. 2020;217(12).
15. Nicolai L, Leunig A, Brambs S, et al. Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy. *Circulation*. 2020;142(12):1176-1189.
16. Urban CF, Ermert D, Schmid M, et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. *PLoS Pathog*. 2009;5(10):e1000639.
17. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. *Nat Med*. 2009;15(11):1318-1321.
18. Yang R, Tenhunen J, Tonnessen TI. HMGB1 and Histones Play a Significant Role

in Inducing Systemic Inflammation and Multiple Organ Dysfunctions in Severe Acute Pancreatitis. *International Journal of Inflammation*. 2017;2017:1817564.

19. Lv X, Wen T, Song J, et al. Extracellular histones are clinically relevant mediators in the pathogenesis of acute respiratory distress syndrome. *Respir Res*. 2017;18(1):165.

20. Abrams ST, Zhang N, Manson J, et al. Circulating histones are mediators of trauma-associated lung injury. *Am J Respir Crit Care Med*. 2013;187(2):160-169.

21. Saffarzadeh M, Juenemann C, Queisser MA, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. *PLoS One*. 2012;7(2):e32366.

22. Silvestre-Roig C, Braster Q, Wichapong K, et al. Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. *Nature*. 2019;569(7755):236-240.

23. Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT. Extracellular Histones Are Mediators of Death through TLR2 and TLR4 in Mouse Fatal Liver Injury. *The Journal of Immunology*. 2011;187(5):2626.

24. Allam R, Scherbaum CR, Darisipudi MN, et al. Histones from Dying Renal Cells Aggravate Kidney Injury via TLR2 and TLR4. *Journal of the American Society of Nephrology*. 2012;23(8):1375.

25. Kim JE, Yoo HJ, Gu JY, Kim HK. Histones Induce the Procoagulant Phenotype of Endothelial Cells through Tissue Factor Up-Regulation and Thrombomodulin Down-Regulation. *PLoS One*. 2016;11(6):e0156763.

26. Allam R, Darisipudi MN, Tschopp J, Anders HJ. Histones trigger sterile inflammation by activating the NLRP3 inflammasome. *Eur J Immunol*. 2013;43(12):3336-3342.

27. Shi C-x, Wang Y, Chen Q, Jiao F-z, Pei M-h, Gong Z-j. Extracellular Histone H3 Induces Pyroptosis During Sepsis and May Act Through NOD2 and VSIG4/NLRP3 Pathways. *Frontiers in Cellular and Infection Microbiology*. 2020;10(196).

28. Lam FW, Cruz MA, Parikh K, Rumbaut RE. Histones stimulate von Willebrand factor release in vitro and in vivo. *Haematologica*. 2016;101(7):e277-279.

29. Sol A, Skvirsky Y, Blotnick E, Bachrach G, Muhlrad A. Actin and DNA Protect Histones from Degradation by Bacterial Proteases but Inhibit Their Antimicrobial Activity. *Frontiers in Microbiology*. 2016;7(1248).

30. Meara CHO, Coupland LA, Kordbacheh F, et al. Neutralizing the pathological effects of extracellular histones with small polyanions. *Nat Commun*. 2020;11(1):6408.

31. Palmer KJ, Goa KL. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. *Drugs*. 1993;45(2):259-294.

32. Kornblum N, Ayyanar K, Benimetskaya L, Richardson P, Iacobelli M, Stein CA. Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. *Oligonucleotides*.

2006;16(1):105-114.

33. Pescador R, Capuzzi L, Mantovani M, Fulgenzi A, Ferrero ME. Defibrotide: Properties and clinical use of an old/new drug. *Vascular Pharmacology*. 2013;59(1):1-10.

34. Richardson PG, Corbacioglu S, Ho VT, et al. Drug safety evaluation of defibrotide. *Expert Opin Drug Saf*. 2013;12(1):123-136.

35. Eissner G, Multhoff G, Gerbitz A, et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. *Blood*. 2002;100(1):334-340.

36. Bracht F, Schror K. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. *Biochem Biophys Res Commun*. 1994;200(2):933-937.

37. Coccheri S, Biagi G, Legnani C, Bianchini B, Grauso F. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. *Eur J Clin Pharmacol*. 1988;35(2):151-156.

38. Berti F, Rossoni G, Biasi G, Buschi A, Mandelli V, Tondo C. Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1 induced contraction in human saphenous veins. *Prostaglandins*. 1990;40(4):337-350.

39. Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. *Thromb Haemost*. 1994;71(4):507-510.

40. Benimetskaya L, Wu S, Voskresenskiy AM, et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. *Blood*. 2008;112(10):4343-4352.

41. Folco EJ, Mawson TL, Vromman A, et al. Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin-1α and Cathepsin G. *Arteriosclerosis, thrombosis, and vascular biology*. 2018;38(8):1901-1912.

42. Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. *JCI insight*. 2020;5(11):e138999.

43. Silk E, Zhao H, Weng H, Ma D. The role of extracellular histone in organ injury. *Cell death & disease*. 2017;8(5):e2812-e2812.

44. Kawai C, Kotani H, Miyao M, et al. Circulating Extracellular Histones Are Clinically Relevant Mediators of Multiple Organ Injury. *The American Journal of Pathology*. 2016;186(4):829-843.

45. Kumar SVR, Kulkarni OP, Mulay SR, et al. Neutrophil Extracellular Trap-Related Extracellular Histones Cause Vascular Necrosis in Severe GN. *Journal of the American Society of Nephrology*. 2015;26(10):2399.

46. Hellman LM, Fried MG. Electrophoretic mobility shift assay (EMSA) for detecting protein–nucleic acid interactions. *Nature Protocols*. 2007;2(8):1849-1861.

47. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. *Nature Medicine*. 2009;15(11):1318-1321.

48. Volchuk A, Ye A, Chi L, Steinberg BE, Goldenberg NM. Indirect regulation of HMGB1 release by gasdermin D. *Nat Commun*. 2020;11(1):4561.

49. Ali RA, Gandhi AA, Meng H, et al. Adenosine receptor agonism protects against

NETosis and thrombosis in antiphospholipid syndrome. *Nature Communications*. 2019;10(1):1916.

50. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. *Nat Rev Immunol*. 2018;18(2):134-147.

51. Urbinati C, Chiodelli P, Rusnati M. Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis. *Molecules*. 2008;13(11):2758-2785.

52. Lindahl U, Lidholt K, Spillmann D, Kjellén L. More to "heparin" than anticoagulation. *Thromb Res*. 1994;75(1):1-32.

53. Volpi N. Therapeutic applications of glycosaminoglycans. *Curr Med Chem*. 2006;13(15):1799-1810.

54. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. *Curr Pharm Des*. 2007;13(20):2025-2044.

55. Rusnati M, Tulipano G, Urbinati C, et al. The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. *J Biol Chem*. 1998;273(26):16027-16037.

56. Finch PW, Yee LK, Chu MY, et al. Inhibition of growth factor mitogenicity and growth of tumor cell xenografts by a sulfonated distamycin A derivative. *Pharmacology*. 1997;55(6):269-278.

57. Eberle RJ, Coronado MA, Peinado RS, et al. The polyanions heparin and suramin impede binding of free adenine to a DNA glycosylase from C. pseudotuberculosis. *Int J Biol Macromol*. 2019;125:459-468.

58. Richmond TJ, Davey CA. The structure of DNA in the nucleosome core. *Nature*. 2003;423(6936):145-150.

59. Semeraro F, Ammollo CT, Morrissey JH, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. *Blood*. 2011;118(7):1952-1961.

60. Silvestre-Roig C, Braster Q, Wichapong K, et al. Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. *Nature*. 2019;569(7755):236-240.

61. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. *Ann Surg*. 1992;216(2):117-134.

62. Beal AL, Cerra FB. Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. *Jama*. 1994;271(3):226-233.

63. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. *Crit Care Med*. 1995;23(10):1638-1652.

64. Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. *Crit Care Med*. 1998;26(11):1793-1800.

65. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ

dysfunction syndrome. *Crit Care Med*. 2001;29(7 Suppl):S99-106.

66. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18(6):1421-1424.

67. Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020;191:145-147.

68. Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. *Sci Transl Med*. 2020;12(570).

69. Fajgenbaum DC, June CH. Cytokine Storm. *N Engl J Med*. 2020;383(23):2255-2273.

70. Cervera R, Rodriguez-Pinto I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. *J Autoimmun*. 2018;92:1-11.

71. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. *Am J Emerg Med*. 2008;26(6):711-715.

72. Cheng Z, Abrams ST, Alhamdi Y, et al. Circulating Histones Are Major Mediators of Multiple Organ Dysfunction Syndrome in Acute Critical Illnesses. *Crit Care Med*. 2019;47(8):e677-e684.

73. Zuo Y, Yalavarthi S, Gockman K, et al. Anti-Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome. *Arthritis Rheumatol*. 2020;72(12):2130-2135.

74. Feoktistova M, Geserick P, Leverkus M. Crystal Violet Assay for Determining Viability of Cultured Cells. *Cold Spring Harb Protoc*. 2016;2016(4):pdb.prot087379.

ACKNOWLEDGEMENTS

The authors thank Doruk Erkan (Hospital for Special Surgery) for helpful discussions regarding potential roles of defibrotide in thromboinflammatory diseases. YZ was supported by a career development grant from the Rheumatology Research Foundation. YK was supported by the Intramural Research Program of the NIH and NHLBI, Lasker Foundation, NIH (K08HL131993, R01HL150392), Falk Medical Research Trust Catalyst Award, and the JOBST-American Venous Forum Award. JHM and SAS were supported by the NIH (R35 HL135823). JSK was additionally supported by grants from the NIH (R01HL115138), Burroughs Wellcome Fund, Rheumatology Research Foundation, and Lupus Research Alliance.

AUTHORSHIP

HS, AAG, SS, DC, SY, RAA, CL, GS, and P-ST conducted experiments and analyzed data. HS, YZ, YK, JHM, and JSK conceived the study and analyzed data. All authors participated in writing the manuscript and gave approval before submission.

DISCLOSURES

The authors have no relevant financial conflicts to report. Defibrotide was provided by Jazz Pharmaceuticals. The work was also partially supported by a grant from Jazz Pharmaceuticals, which did not participate in study design or data analysis.

Figure 1: Defibrotide inhibits the activation of cultured HUVECs by NETs. A-C, HUVECs were pretreated with defibrotide (10 µg/ml) for 30 minutes, followed by isolated NETs (1 µg DNA content/ml) for 4 hours. E-selectin (A), ICAM-1 (B), and VCAM-1 (C) mRNA levels were determined by qPCR. Mean ± standard deviation is presented for one representative experiment out of three independent experiments; ****p<0.0001 by one-way ANOVA corrected by Dunnett's test. **D,** HUVEC monolayers were pretreated with defibrotide (10 µg/ml) for 30 minutes, followed by NETs (1 µg DNA content/ml) for 4 hours. Calcein-AM-labeled neutrophils were then added as described in Methods. Mean ± standard deviation is presented for n=3 independent experiments; **p < 0.01 and ***p < 0.001 by one-way ANOVA corrected by Dunnett's test. **E-F,** HUVECs were treated as for panels A-C. Tissue factor mRNA levels (E) and activity (F) were detected at 4 hours. Mean ± standard deviation is presented for n=3 independent experiments; *p<0.05, **p<0.01, and ****p<0.0001 as compared by one-way ANOVA corrected by Dunnett's test.

Figure 2: Defibrotide reduces HUVEC activation by NETs and COVID-19 serum as determined by in-cell ELISA. A, Schematic workflow for in-cell ELISA. **B-D,** HUVECs were pretreated with defibrotide (10 µg/ml) for 30 minutes, followed by the addition of NETs for 6 hours. Surface expression of E-selectin (B), ICAM-1 (C), and VCAM-1 (D) were then detected by in-cell ELISA. **E-G,** HUVECs were pretreated with defibrotide (20 µg/ml) for 30 min, followed by the addition of 2.5% COVID-19 serum (pooled from n=5 patients with severe disease and high circulating NETs) for 6 hours. Surface E-selectin (E), ICAM-1 (F), and VCAM-1 (G) expressions were then detected by in-cell ELISA. Mean ± standard deviation is presented for n=3 independent experiments; *p<0.05, **p<0.01, and ***p<0.001 by one-way ANOVA corrected by Dunnett's test. DF=defibrotide, TMB=tetramethylbenzidine, OD=optical density.

Figure 3: Transcriptome profiling of HUVECs in response to NETs ± defibrotide. A, HUVECs were treated with vehicle (PBS), NETs (1 μg DNA content/ml), or NETs+defibrotide (10 μg/ml) for 4 hours (n=3 per group). RNA sequencing was performed. K-means clustering of differentially expressed genes is presented as a heat map. **B,** Bubble plot of upregulated biological processes in the NETs group as compared with the vehicle group. Color-coding is based on p value and bubble size is based on the number of genes in each pathway. **C,** Bubble plot of downregulated biological processes in the NETs group as compared with the NETs+defibrotide group. **D,** Bubble plot of downregulated biological processes in the

NETs group as compared with the vehicle group. **E,** Bubble plot of upregulated biological processes in the NETs+defibrotide group as compared with the NETs group. DF=defibrotide.

Figure 4: NET-derived histone H4 induces HUVEC activation. A-D, NETs (1 µg DNA content/ml) were incubated with antibodies to histone H4 (100 ng/ml) for 1h, and then added to HUVECs for 4 hours. E-selectin (A), ICAM-1 (B), VCAM-1 (C) and tissue factor (TF) mRNA levels were determined by qPCR. Mean ± standard deviation is presented for one representative experiment out of three independent experiments; *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001 one-way ANOVA corrected by Sidak's or Tukey's test.

Figure 5: Defibrotide abolishes HUVEC activation by extracellular histone H4.
A-D, HUVECs were pretreated with defibrotide (10 μg/ml) for 30 minutes, followed by recombinant histone H4 (25 μg/ml) for 4 hours. E-selectin (A), ICAM-1 (B), VCAM-1 (C), and tissue factor (D) mRNA levels were determined by qPCR. Mean ± standard deviation is presented for one representative experiment out of three independent experiments; ****$p < 0.0001$ by one-way ANOVA corrected by Dunnett's test. **E,**

HUVEC lysates were prepared and tissue factor activity was determined as described in Methods. Mean ± standard deviations are presented for n=3 independent experiments; *p<0.05 and **p<0.01 by one-way ANOVA corrected by Dunnett's test. **F,** Defibrotide and histone H4 were incubated at 37°C for 30 minutes and then resolved on a 0.5% agarose gel. **G,** Surface plasmon resonance assay characterizing the binding kinetics of defibrotide to histone H4. The profile of defibrotide at gradient concentrations (from 0.39 µg/ml to 12.5 µg/ml) flowing over histone H4 protein immobilized on a NiNTA chip are shown. The calculated dissociation constant (K_D) is labeled.

Figure 6: Defibrotide protects HUVECs from histone H4-mediated cell death. A,
HUVECs were treated with different doses of histone H4 (0, 25, 50, and 100 µg/ml) in
the presence or absence of defibrotide (20 µg/ml). After 24 hours, HUVECs were
stained with crystal violet solution for 10 minutes, and absorbance was measured at

570 nm to determine cell viability. Mean ± standard deviation for three independent experiments, along with representative images, are presented; ***p<0.001 and ****p<0.0001 by one-way ANOVA corrected by Dunnett's test. **B,** HUVECs were treated with histone H4 and different doses of defibrotide in the presence of Annexin V red agent. The plate was imaged every hour using the IncuCyte® S3 timelapse microscope for 30 hours. Mean ± standard deviation for three independent experiments is presented; **p<0.01 and ***p<0.001 by two-way ANOVA corrected by Dunnett's test. **C-D,** HUVECs were treated with histone H4 (100 μg/ml) ± defibrotide (20 μg/ml) for 4 hours. The concentrations of IL-1β (C) and IL-18 (D) were determined in supernatants (n=6 independent experiments); ***p<0.001 and ****p<0.0001 by one-way ANOVA corrected by Dunnett's test. **E-F,** HUVECs were treated as in panels C-D, and HMGB1 translocation (E) and secretion (F) were determined by microscopy and supernatant ELISA, respectively (n=3 independent experiments); ****p<0.0001 by one-way ANOVA corrected by Dunnett's test. Scale bars are 100 microns (primary image) and 10 microns (inset).

Figure 7: Defibrotide alleviates histone-mediated endothelial activation and venous thrombosis in mice. A, Thrombus initiation in the IVC via placement of a fixed suture over a spacer that was subsequently removed. **B,** Mice were injected with either histone (10 mg/kg) or saline via tail vein 1 hour prior to surgery.

Meanwhile, defibrotide (150 mg/kg) or saline was administered by retro-orbital injection 24 hours prior to surgery and then immediately following closure of the abdomen. Thrombus weight was determined 24 hours later. Scatter plots are presented with each data point representing a unique mouse (horizontal bars=means; *p<0.05 and **p<0.01 by one-way ANOVA corrected by Sidak's test. **C,** Representative thrombi from the experiments presented in panel B with rulers measuring thrombi in millimeters. **D-E,** Serum samples from the experiments presented in panel B were tested for soluble E-selectin (D) and soluble P-selectin (E) by ELISA; *p<0.05, **p<0.01, and ***p<0.001 by one-way ANOVA corrected by Sidak's test. **F-H,** Thrombus sections from panel B were stained for Ly6G and CD45-positive cells. Positively-stained cells were quantified in four randomly selected fields for each thrombus. **p<0.01 and ***p<0.001 by one-way ANOVA corrected by Sidak's test. Scare bar=1000 microns.

Supplementary Materials

Endothelium-protective histone-neutralizing properties of the polyanionic agent defibrotide

Shi *et al.*

Supplementary Figure 1: Defibrotide protects HUVECs from histone H4-mediated chemokine secretion. HUVECs were treated with histone H4 (25 µg/ml) ± defibrotide (10 µg/ml) for 4 hours. The concentrations of IL-8 (A) and MCP-1 (B) were determined in supernatants (n=6 independent experiments); ****$p < 0.0001$ by one-way ANOVA corrected by Dunnett's test.

Supplementary Figure 2: Toll-like receptor inhibitors mitigate the activation of cultured HUVECs by histone H4. A-D, HUVECs were pretreated with C29 (TLR2 inhibitor) or TAK242 (TLR4 inhibitor) for 1 hour, followed by the addition of histone H4 (25 µg/ml) for 4 hours. E-selectin (A), ICAM-1 (B), VCAM-1 (C) and tissue factor (D) mRNA levels were determined by quantitative PCR. Mean ± standard deviation is presented for one representative experiment out of three independent experiments; *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001 by one-way ANOVA corrected by Dunnett's test.

Supplementary Figure 3: Defibrotide does not inhibit the activation of cultured HUVECs by either TNF-α or LPS. A-D, HUVECs were pretreated with defibrotide (20 or 40 μg/ml) for 30 minutes, followed by TNF-α (20 nM) or LPS (1 μg/ml) for 4 hours. E-selectin (A), ICAM-1 (B), VCAM-1 (C), and tissue factor (D) mRNA levels were determined by qPCR. Mean ± standard deviation is presented for one representative experiment out of three independent experiments. No comparisons were statistically significant.

Supplementary Figure 4: HUVECs expose phosphatidylserine in response to histone H4. HUVECs were treated with different concentrations of histone H4 in the presence of Annexin V red agent. The plate was imaged every hour using the IncuCyte® S3 timelapse microscope for 30 hours. Mean ± standard deviation for three independent experiments is presented; ****p<0.0001by two-way ANOVA corrected by Dunnett's test.

Supplementary Figure 5: Defibrotide reduces the length of histone-mediated venous thrombi. Mice were injected with either histone (10 mg/kg) or saline via tail vein 1 hour prior to surgery via tail. Meanwhile, defibrotide (150 mg/kg) or saline was administered by retro-orbital injection 24 hours prior to surgery and then immediately following closure of the abdomen. Thrombus length was determined 24 hours later. Scatter plots are presented with each data point representing a unique mouse (horizontal bars=means; *p<0.05 by one-way ANOVA corrected by Sidak's test.

Supplementary Figure 6: Association between serum E-selectin or soluble P-selectin and thrombus size in mice. A-D, The data presented in Figure 7 and Supplementary Figure 5 are presented here as scatter plots. Correlations were tested by Pearson's method.